By Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics Corporation.
Founded in 1996, United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have four approved products on the market today and we are not stopping there! From the United States to Europe to the Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”® and continue our research into treatments for pulmonary arterial hypertension, cancer, and some of the world’s most complicated viral illnesses.
We are proud to partner with Research!America to promote better medical advancements, biomedical research, and overall greater global health initiatives. We have seen first-hand how tireless research and dedication to a cause can change the lives of thousands of patients and their loved ones. We began our story by conducting extensive research on a treatment for a deadly disease so rare, Pulmonary Arterial Hypertension (PAH), that other medical companies had abandoned any pursuits for treatments or a cure.
Far too often, orphan diseases – diseases with fewer than 200,000 people by U.S. standards – are ignored by larger pharmaceutical companies because the number of patients is considered too small to warrant the resources that would be used. This unmet need is a major challenge facing researchers today. More government funding and support for orphan diseases could make a difference in millions of lives. We have experienced this first hand, and have shown how even orphan diseases are worth researching and treating.
United Therapeutics has been successful in our pursuit for PAH treatments, however, we are still working on newer and better treatments, on our road to a cure. Currently, we are researching innovative ways to extend lung transplantation options, which would provide a cure to so many people suffering various lung diseases, including PAH. These models include xenotransplantation, as well as groundbreaking research into extending the usability of human lung donations, that would normally be considered marginal for use in transplants.
Research is the first step in any successful endeavor. We have built our company on this fact, and continue to grow with this in mind. For more information about United Therapeutics Corporation, please visit our website at: http://www.unither.com.